19 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable stearoyl-CoA desaturase-1 (SCD1) inhibitors: part 2. Pyridazine-based analogs.
Janssen Research And Development
4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable Stearoyl-CoA desaturase-1 (SCD1) inhibitors. Part 1: urea-based analogs.
Janssen Research And Development
Benzimidazole-carboxamides as potent and bioavailable stearoyl-CoA desaturase (SCD1) inhibitors from ligand-based virtual screening and chemical optimization.
Sanofi-Aventis Deutschland
Discovery of liver-targeted inhibitors of stearoyl-CoA desaturase (SCD1).
Merck Research Laboratories
Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia.
Merck Frosst Centre For Therapeutic Research
Discovery of potent and liver-selective stearoyl-CoA desaturase (SCD) inhibitors in an acyclic linker series.
Merck Frosst Centre For Therapeutic Research
Nicotinic acids: liver-targeted SCD inhibitors with preclinical anti-diabetic efficacy.
Merck Frosst Centre For Therapeutic Research
Discovery of potent and liver-targeted stearoyl-CoA desaturase (SCD) inhibitors in a bispyrrolidine series.
Merck Frosst Centre For Therapeutic Research
Conversion of systemically-distributed triazole-based stearoyl-CoA desaturase (SCD) uHTS hits into liver-targeted SCD inhibitors.
Merck Frosst Centre For Therapeutic Research
Bicyclic heteroaryl inhibitors of stearoyl-CoA desaturase: from systemic to liver-targeting inhibitors.
Merck Frosst Centre For Therapeutic Research
N-benzylimidazole carboxamides as potent, orally active stearoylCoA desaturase-1 inhibitors.
Pfizer
2-Aryl benzimidazoles: human SCD1-specific stearoyl coenzyme-A desaturase inhibitors.
Merck Frosst Centre For Therapeutic Research
SAR and optimization of thiazole analogs as potent stearoyl-CoA desaturase inhibitors.
Merck Frosst Centre For Therapeutic Research
Synthesis and biological activity of a potent and orally bioavailable SCD inhibitor (MF-438).
Merck Frosst Centre For Therapeutic Research
Thiazole analog as stearoyl-CoA desaturase 1 inhibitor.
Merck Frosst Centre For Therapeutic Research
Potent, orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors.
Gilead Sciences